← Eichor
Condition: Waldenstrom Macroglobulinemia Wm Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Waldenstrom Macroglobulinemia Wm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings
Phase N/A · 1 location(s) · Rigshospitalet, Denmark · NCT07160270Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05914662Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase N/A · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT00923507Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Z
Phase 2 · 136 location(s) · National Cancer Institute (NCI) · NCT04840602Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractor
Phase 2 · 17 location(s) · AbbVie · NCT07387471A Study of ARC-02 in B-cell NHL
Phase 1 · 29 location(s) · Taiho Oncology, Inc. · NCT07691606Epcoritamab in Previously Treated WM
Phase 2 · 3 location(s) · Gottfried von Keudell, MD PhD · NCT06510491A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 16 location(s) · Nurix Therapeutics, Inc. · NCT04830137Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Phase 2 · 5 location(s) · Massachusetts General Hospital · NCT06561347Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and
Phase N/A · 2 location(s) · iOMEDICO AG · NCT05326308A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacyti
Phase 2 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT07231952A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 62 location(s) · Nurix Therapeutics, Inc. · NCT05131022Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Phase 1/Phase 2 · 2 location(s) · ModeX Therapeutics, An OPKO Health Company · NCT07249905
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.